{
  "ticker": "PAB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977447",
  "id": "02977447",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250806",
  "time": "0950",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml9mhl7g06bn.pdf",
  "summary": "**Capital Raising Announcement**  \n- **Structure**: Pro-rata non-renounceable entitlement offer (3:4 ratio) + free attaching shares (1:4 ratio).  \n- **Capital Raised**: Up to **$1.77M AUD** (before costs) at **$0.001/share**.  \n- **Key Dates**: Record date not specified; general meeting for approvals scheduled for **August 2025**.  \n- **Underwritten**: Fully underwritten by Templar Corporate Pty Ltd.  \n- **Use of Funds**: Technical work for deoxymabs, IP maintenance, business development, working capital.  \n- **Post-Offer Capital Structure**: ~4.58B shares on issue if fully subscribed (incl. 443.6M free attaching shares).  \n- **Options Issuance**: Up to **1.03B unlisted options** to underwriter (exercise price $0.0016, expiry Nov 2029).  \n- **Ineligible Shareholders**: Excluded due to jurisdictional costs.  \n\n*(Omitted: Broker/placement options, fee structures, prospectus references.)*",
  "usage": {
    "prompt_tokens": 1487,
    "completion_tokens": 232,
    "total_tokens": 1719,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T23:58:17.247889"
}